HighTower Advisors’s Krystal Biotech KRYS Stock Holding History
Bought
Maintained
Sold
Other funds holding KRYS
HighTower Advisors's KRYS Position: Q3 2026 in Review
HighTower Advisors increased its Krystal Biotech (KRYS) stake by 12% in Q3 2026, buying an estimated $91.8K and bringing the position to 2,394 shares worth $796K. The position accounts for ﹤0.01% of the portfolio, ranked #2413.
HighTower Advisors first reported a position in KRYS in Q4 2025 and has held it in 4 quarters since. 388 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.
- HighTower Advisors held 2,394 shares of Krystal Biotech worth $796K as of Q3 2026.
- HighTower Advisors bought 265 Krystal Biotech shares in Q3 2026, an estimated $91.8K.
- Krystal Biotech made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #2413 holding.
- HighTower Advisors first reported a position in Krystal Biotech in Q4 2025 and has held it in 4 quarters since.
- 388 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.
Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.